Expertise in
1
conditions

Lothar Bergmann

Heidelberg, BW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Heidelberg, BW, DE 

Overview

Lothar Bergmann practices in Heidelberg, Germany. Mr. Bergmann is highly rated in 1 condition, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC) and Pancreatic Cancer.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Heidelberg, BW, Germany
Other Locations
Frankfurt Am Main, HE, Germany
Geesthacht, SH 21502, Germany
Essen, NW 45147, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 23, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

66 Total Publications

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.
Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.
Journal: Physical review letters
Published: October 30, 2024

Frequently Asked Questions about Lothar Bergmann

Is Lothar Bergmann a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Lothar Bergmann is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lothar Bergmann participate in research or clinical trials?

Yes. Lothar Bergmann has published 66 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Lothar Bergmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bergmann's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile